A. Trout

888 total citations
15 papers, 673 citations indexed

About

A. Trout is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, A. Trout has authored 15 papers receiving a total of 673 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in A. Trout's work include Bladder and Urothelial Cancer Treatments (13 papers), Renal cell carcinoma treatment (10 papers) and Multiple and Secondary Primary Cancers (5 papers). A. Trout is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Renal cell carcinoma treatment (10 papers) and Multiple and Secondary Primary Cancers (5 papers). A. Trout collaborates with scholars based in United States, Russia and Ireland. A. Trout's co-authors include Matthew I. Milowsky, Dean F. Bajorin, Jamie C. Riches, David Gallagher, Ashley Marie Regazzi, Scott R. Gerst, Andrea B. Apolo, Nicole Ishill, Ilana Garcia-Grossman and Irina Ostrovnaya and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Urology.

In The Last Decade

A. Trout

15 papers receiving 668 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Trout United States	9	475	223	221	210	88	15	673
Maria Del Carmen Rodriguez Peña United States	16	347 0.7×	223 1.0×	193 0.9×	138 0.7×	97 1.1×	29	624
Satinder Jagdev United Kingdom	11	343 0.7×	165 0.7×	248 1.1×	244 1.2×	37 0.4×	24	569
Donatella Tirindelli Danesi Italy	12	252 0.5×	140 0.6×	131 0.6×	158 0.8×	44 0.5×	24	495
L. Ibarz Spain	8	240 0.5×	147 0.7×	128 0.6×	111 0.5×	118 1.3×	14	428
Nicole N. Davarpanah United States	13	232 0.5×	84 0.4×	140 0.6×	223 1.1×	72 0.8×	21	417
Roosevelt Anderson United States	5	211 0.4×	105 0.5×	114 0.5×	166 0.8×	164 1.9×	5	442
Thiagarajan Sreenivasan United Kingdom	6	607 1.3×	139 0.6×	126 0.6×	208 1.0×	57 0.6×	6	808
Estrella M. Carballido United States	12	185 0.4×	120 0.5×	175 0.8×	264 1.3×	79 0.9×	27	499
Shinya Ohara Japan	12	135 0.3×	115 0.5×	152 0.7×	159 0.8×	43 0.5×	29	376
Pieter De Mulder Netherlands	6	140 0.3×	107 0.5×	91 0.4×	103 0.5×	50 0.6×	9	349

Countries citing papers authored by A. Trout

Since Specialization

Citations

This map shows the geographic impact of A. Trout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Trout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Trout more than expected).

Fields of papers citing papers by A. Trout

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Trout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Trout. The network helps show where A. Trout may publish in the future.

Co-authorship network of co-authors of A. Trout

This figure shows the co-authorship network connecting the top 25 collaborators of A. Trout. A scholar is included among the top collaborators of A. Trout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Trout. A. Trout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Milowsky, Matthew I., Gopa Iyer, Ashley Marie Regazzi, et al.. (2013). Phase II study of everolimus in metastatic urothelial cancer. British Journal of Urology. 112(4). 462–470. 128 indexed citations

Balar, Arjun Vasant, Andrea B. Apolo, Irina Ostrovnaya, et al.. (2013). Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer. Journal of Clinical Oncology. 31(6). 724–730. 71 indexed citations

Gallagher, David, Hikmat Al‐Ahmadie, Irina Ostrovnaya, et al.. (2011). Sunitinib in Urothelial Cancer: Clinical, Pharmacokinetic, and Immunohistochemical Study of Predictors of Response. European Urology. 60(2). 344–349. 16 indexed citations

Balar, Arjun Vasant, Matthew I. Milowsky, Andrea B. Apolo, et al.. (2011). Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology. 29(7_suppl). 248–248. 3 indexed citations

Milowsky, Matthew I., Ashley Marie Regazzi, Ilana Garcia-Grossman, et al.. (2011). Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium.. Journal of Clinical Oncology. 29(7_suppl). 245–245. 5 indexed citations

Balar, Arjun Vasant, Matthew I. Milowsky, Andrea B. Apolo, et al.. (2011). Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology. 29(15_suppl). 4566–4566. 2 indexed citations

Milowsky, Matthew I., Ashley Marie Regazzi, Ilana Garcia-Grossman, et al.. (2011). Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium.. Journal of Clinical Oncology. 29(15_suppl). 4606–4606. 10 indexed citations

Apolo, Andrea B., Jamie C. Riches, Heiko Schöder, et al.. (2010). Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer. Journal of Clinical Oncology. 28(25). 3973–3978. 125 indexed citations

Gallagher, David, Matthew I. Milowsky, Scott R. Gerst, et al.. (2010). Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer. Journal of Clinical Oncology. 28(8). 1373–1379. 145 indexed citations

10.

Gallagher, David, Matthew I. Milowsky, Scott R. Gerst, et al.. (2009). A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). Journal of Clinical Oncology. 27(15_suppl). 5072–5072. 7 indexed citations

11.

Gallagher, David, Matthew I. Milowsky, Nicole Ishill, et al.. (2008). Detection of circulating tumor cells in patients with urothelial cancer. Annals of Oncology. 20(2). 305–308. 75 indexed citations

12.

Milowsky, Mathew I., Nicole Ishill, Jamie C. Riches, et al.. (2008). Circulating tumor cells in patients with metastatic urothelial cancer. Journal of Clinical Oncology. 26(15_suppl). 16054–16054. 1 indexed citations

13.

Gallagher, David, Matthew I. Milowsky, Scott R. Gerst, et al.. (2008). Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). Journal of Clinical Oncology. 26(15_suppl). 5082–5082. 10 indexed citations

14.

Posadas, Edwin M., James L. Gulley, Philip M. Arlen, et al.. (2005). A phase II study of perifosine in androgen independent prostate cancer. Cancer Biology & Therapy. 4(10). 1133–1137. 74 indexed citations

15.

Retter, Avi S., Philip M. Arlen, James L. Gulley, et al.. (2005). A phase II trial of docetaxel (D), estramustine (E) and thalidomide (T) in patients with metastatic androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology. 23(16_suppl). 4764–4764. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact